Gene therapy for Parkinson's shows potential for alcohol use disorder in OHSU study
The procedure was shown to reduce alcohol consumption by 90% compared to a control group. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 14, 2023 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

What Happens When a $2 Million Gene Therapy Is Not Enough What Happens When a $2 Million Gene Therapy Is Not Enough
Baby Ben Kutschke was diagnosed at 3 months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2023 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Insight: What happens when a $2 million gene therapy is not enough
[1/5] Elizabeth Kutschke spends time at the park with her 2-year-old son, Ben, who was diagnosed with spinal muscular atrophy, an inherited disorder which is the leading genetic cause of death in infancy globally and leaves children too weak to walk, talk, swallow or even breathe, in Oak Park,...…#elizabethkutschke #oakpark #babybenkutschke #berwyn #illinois #sma #healthcare #novartis #medicaid #rogerhajjar (Source: Reuters: Health)
Source: Reuters: Health - August 12, 2023 Category: Consumer Health News Source Type: news

What happens when a $2 million gene therapy is not enough
Baby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally. It leaves children too weak to walk, talk, swallow or even breathe. So when in 2021 his parents heard about Zolgensma – a…#babybenkutschke #elizabethkutschke #berwyn #illinois #sma #healthcare #novartis #medicaid #rogerhajjar #kutschke (Source: Reuters: Health)
Source: Reuters: Health - August 12, 2023 Category: Consumer Health News Source Type: news

Gene therapy hope for children with kidney disease
Researchers at the University of Bristol have made a remarkable step forward in finding a potential cure for a type of childhood kidney disease. (Source: University of Bristol news)
Source: University of Bristol news - August 10, 2023 Category: Universities & Medical Training Tags: Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news

Regeneron to buy Boston-based hearing loss biotech for $213M
The Tarrytown, New York-based drugmaker has its sights set on Decibel Therapeutics, which develops gene therapies designed to treat various forms of hearing loss. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 9, 2023 Category: Biotechnology Authors: Rowan Walrath Source Type: news

FDA-approved gene therapy invented at Nationwide Children's carries a $3.2M price tag. Here's why.
On Wednesday, a 5-year-old boy in Washington, D.C., received the first infusion with FDA-approved Elevidys, a gene therapy invented at Nationwide Children's Hospital for Duchenne muscular dystrophy, which usually kills by age 30. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 4, 2023 Category: Pharmaceuticals Authors: Carrie Ghose Source Type: news

How Nationwide Children's Hospital research is fueling a gene therapy industry center in Central Ohio
Investments Children ’s started two decades ago and collaborations with Ohio State University have led to a blossoming cell and gene therapy industry in Central Ohio. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 4, 2023 Category: Biotechnology Authors: Carrie Ghose Source Type: news

Gene Therapy for the Health-Care Professional Gene Therapy for the Health-Care Professional
Join Dr Beverly L. Davidson as she reviews the principles underlying gene therapy and the different techniques used in its application.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 3, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news

The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets
Peter Hecht, the co-founder and CEO of embattled biotech Cyclerion Therapeutics Inc. (Nasdaq: CYCN), is heading up a new startup that's effectively a life raft for Cyclerion's research. Elsewhere in the Petri Dish: a $1 billion deal for Pfizer gene therapies, a succession plan for a founder-led biotech organization, and a new Longwood Fund spinout with assets from GSK. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 3, 2023 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

Gene therapy startup founded by Pfizer, Biogen vet to shut down
Another biotech bites the dust: A startup that launched in 2021 to advance nonviral gene therapies has laid off all its employees and is exploring a sale. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 1, 2023 Category: Biotechnology Authors: Rowan Walrath Source Type: news

Study: AMD Gene Therapy Demonstrates Vision Stabilization Study: AMD Gene Therapy Demonstrates Vision Stabilization
An early gene therapy trial reported maintenance of vision, reduced retinal inflammation, and detectable therapeutic protein levels 9 months after treatment for age-related macular degeneration.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 1, 2023 Category: Drugs & Pharmacology Tags: Ophthalmology News Source Type: news

Gene Therapy Solutions For Age-Related Macular Degeneration
Gene therapy is currently one of the trailblazing treatments for dry age-related macular degeneration under research. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 1, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news

Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies
Alexion, AstraZeneca Rare Disease, announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer). The agreement furthers Alexion and AstraZeneca's commitment to advancing next-generation genomic medicines with the addition of complementary pipeline assets and innovative technologies. (Source: World Pharma News)
Source: World Pharma News - July 31, 2023 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news